Source: People's Daily health client Wang Zhenya
"Have enterprises participated in the seventh national drug collection?" "Which varieties participated?" "Many generic drugs have passed the review, and the competition is fierce again"... On February 18, the seventh batch of national drug collection information has just begun, and the industry has shown a high degree of attention and discussion about this collection.
Xie Yijiong, an industry insider, told the People's Daily health client that the seventh collection was more rigorous and standardized than the previous six. After three years and six collections, the collection and collection work has entered normalization and institutionalization. The seventh collection, large varieties and common disease drugs will be the focus.
The pharmacist is prescribing medicine, the picture comes from Xinhua News Agency.
The largest variety of injections, accounting for 47%
The national collection involved a total of 58 varieties and 208 specifications of drugs, including oncology, diabetes, cardiovascular, nervous system, antibiotics and other disease treatment fields. Xie Yijiong told reporters that the injection is the focus of the collection, involving 27 varieties, accounting for 47%.
The People's Daily health client combed and found that among the 27 injectable varieties, many large varieties exceeded 100 million. According to data from the Intranet, Omeprazole injection and Meropenem injection are large varieties with market sales of more than 3 billion.
Omeprazole injection is mainly used for the treatment of gastric ulcers, duodenal ulcers, etc., it is also known as "gastric miracle drug", in the same kind of treatment of peptic ulcer drug injection products, omeprazole injection ranked first in sales.
Xie Yijiong told reporters that the amount of injections in clinical use is large, and in the previous rounds of collection, the injections included in the collection have subsequently increased. This year, large-scale injections have entered the collection, which is a very important thing for the industry.
A variety of large varieties are included in the collection
"We are not particularly anchored to the international minimum price, Chinese can also take good medicine." On February 11, Chen Jinfu, deputy director of the National Medical Security Bureau, spoke at a regular briefing on centralized drug procurement, which seemed to set the tone for the seventh national collection, and more people commonly used drugs and good drugs to carry out collection.
The People's Daily health client combed and found that there are many good drugs, star drugs and large varieties included in the collection scope. For example, "flu miracle drug" oseltamivir, lung cancer drug afatinib, hypertension drug metoprolol, "stomach disease miracle drug" omeprazole, stroke Chinese medicine edaravon, local anesthesia and anti-arrhythmic drug lidocaine, Alzheimer's disease best-selling drug memantine hydrochloride, etc.
Xie Yijiong introduced that after three years, the reform of centralized procurement with quantity has entered a new stage of normalization and institutionalization, and from the perspective of the results achieved, the overall situation of "price reduction, quantity increase, and quality excellence" has been presented.
For example, after the collection of imatinib, its use increased to 35%, so that patients who need treatment have been fully guaranteed. In addition, in the field of Alzheimer's disease, memantine hydrochloride is the only variety that has entered the collection, which greatly reduces the drug burden on patients.
Competition among domestic and foreign pharmaceutical companies has become more intense
After the first six collections, pharmaceutical companies are more familiar with the rules of national collection, as well as the advantages and disadvantages. Xie Yijiong saw that the competition among pharmaceutical companies will be more intense in this collection, first, because there are many pharmaceutical companies that meet the conditions. The second is because the trend of competition between multinational pharmaceutical companies and local pharmaceutical companies has intensified.
For example, the "flu miracle drug" oseltamivir was previously mainly occupied by East Sunshine and Roche in the Chinese market, with East Sunshine accounting for 90% of the market and Roche accounting for about 10%. In recent years, there are 3 companies in oseltamivir generic drugs, which have passed the consistency evaluation, namely Kelun Pharmaceutical, CSPC Ouyi, and Borui Pharmaceutical. From one of the two to one of the five, the newly entrants will intensify the market competition pattern.
In the field of injections, there are often more companies that can participate in the competition. In 2021, 775 injections have been evaluated, and the enterprises with the largest number of rated varieties are Qilu, CSPC Ouyi, Chia Tai Tianqing Group, Sichuan Kelun and other pharmaceutical companies, which will run this year's collection.
